首页 > 最新文献

Asia-Pacific Journal of Ophthalmology最新文献

英文 中文
Serous Maculopathy Due to Aspecific Choroidopathy (SMACH). 由于非特异性Choroidopathy(SMACH)引起的浆液性黄斑病变。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2022-11-21 DOI: 10.1097/APO.0000000000000550
Elon H C van Dijk, Jeannette Ossewaarde-van Norel, Johannes R Vingerling, Salomon Y Cohen, Camiel J F Boon
{"title":"Serous Maculopathy Due to Aspecific Choroidopathy (SMACH).","authors":"Elon H C van Dijk, Jeannette Ossewaarde-van Norel, Johannes R Vingerling, Salomon Y Cohen, Camiel J F Boon","doi":"10.1097/APO.0000000000000550","DOIUrl":"10.1097/APO.0000000000000550","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40546024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laser Photo-Cauterization for the Management of Exposed Polypropylene Scleral Fixation Sutures. 暴露聚丙烯巩膜固定缝线的激光光烧灼治疗。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2022-11-04 DOI: 10.1097/APO.0000000000000549
Surbhi Agrawal, Divyansh K Mishra, P Mahesh Shanmugam
{"title":"Laser Photo-Cauterization for the Management of Exposed Polypropylene Scleral Fixation Sutures.","authors":"Surbhi Agrawal, Divyansh K Mishra, P Mahesh Shanmugam","doi":"10.1097/APO.0000000000000549","DOIUrl":"10.1097/APO.0000000000000549","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10632194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Artificial Intelligence System for Screening and Recommending the Treatment Modalities for Retinopathy of Prematurity. 用于筛查和推荐早产视网膜病变治疗方式的人工智能系统。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2023-09-22 DOI: 10.1097/APO.0000000000000638
Yaling Liu, Yueshanyi Du, Xi Wang, Xinyu Zhao, Sifan Zhang, Zhen Yu, Zhenquan Wu, Dimitrios P Ntentakis, Ruyin Tian, Yi Chen, Cui Wang, Xue Yao, Ruijiang Li, Pheng-Ann Heng, Guoming Zhang

Purpose: The purpose of this study was to develop an artificial intelligence (AI) system for the identification of disease status and recommending treatment modalities for retinopathy of prematurity (ROP).

Methods: This retrospective cohort study included a total of 24,495 RetCam images from 1075 eyes of 651 preterm infants who received RetCam examination at the Shenzhen Eye Hospital in Shenzhen, China, from January 2003 to August 2021. Three tasks included ROP identification, severe ROP identification, and treatment modalities identification (retinal laser photocoagulation or intravitreal injections). The AI system was developed to identify the 3 tasks, especially the treatment modalities of ROP. The performance between the AI system and ophthalmologists was compared using extra 200 RetCam images.

Results: The AI system exhibited favorable performance in the 3 tasks, including ROP identification [area under the receiver operating characteristic curve (AUC), 0.9531], severe ROP identification (AUC, 0.9132), and treatment modalities identification with laser photocoagulation or intravitreal injections (AUC, 0.9360). The AI system achieved an accuracy of 0.8627, a sensitivity of 0.7059, and a specificity of 0.9412 for identifying the treatment modalities of ROP. External validation results confirmed the good performance of the AI system with an accuracy of 92.0% in all 3 tasks, which was better than 4 experienced ophthalmologists who scored 56%, 65%, 71%, and 76%, respectively.

Conclusions: The described AI system achieved promising outcomes in the automated identification of ROP severity and treatment modalities. Using such algorithmic approaches as accessory tools in the clinic may improve ROP screening in the future.

目的:本研究旨在开发一个人工智能(AI)系统,用于识别早产儿视网膜病变(ROP)的疾病状态并推荐治疗方式,中国,2003年1月至2021年8月。三项任务包括ROP识别、严重ROP识别和治疗模式识别(视网膜激光凝固或玻璃体内注射)。开发AI系统是为了识别这3项任务,特别是ROP的治疗模式。使用额外的200张RetCam图像对人工智能系统和眼科医生之间的性能进行了比较。结果:人工智能系统在3项任务中表现出良好的性能,包括ROP识别[受试者工作特征曲线下面积(AUC),0.9531],严重ROP识别(AUC,0.9132),以及激光光凝或玻璃体内注射的治疗模式识别(AUC,0.9360),以及用于识别ROP的治疗模式的特异性为0.9412。外部验证结果证实了人工智能系统在所有3项任务中的良好性能,准确率为92.0%,优于4名经验丰富的眼科医生,他们的得分分别为56%、65%、71%和76%。结论:所描述的AI系统在ROP严重程度和治疗模式的自动识别方面取得了有希望的结果。在临床中使用这种算法方法作为辅助工具可能会在未来改进ROP筛查。
{"title":"An Artificial Intelligence System for Screening and Recommending the Treatment Modalities for Retinopathy of Prematurity.","authors":"Yaling Liu, Yueshanyi Du, Xi Wang, Xinyu Zhao, Sifan Zhang, Zhen Yu, Zhenquan Wu, Dimitrios P Ntentakis, Ruyin Tian, Yi Chen, Cui Wang, Xue Yao, Ruijiang Li, Pheng-Ann Heng, Guoming Zhang","doi":"10.1097/APO.0000000000000638","DOIUrl":"10.1097/APO.0000000000000638","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to develop an artificial intelligence (AI) system for the identification of disease status and recommending treatment modalities for retinopathy of prematurity (ROP).</p><p><strong>Methods: </strong>This retrospective cohort study included a total of 24,495 RetCam images from 1075 eyes of 651 preterm infants who received RetCam examination at the Shenzhen Eye Hospital in Shenzhen, China, from January 2003 to August 2021. Three tasks included ROP identification, severe ROP identification, and treatment modalities identification (retinal laser photocoagulation or intravitreal injections). The AI system was developed to identify the 3 tasks, especially the treatment modalities of ROP. The performance between the AI system and ophthalmologists was compared using extra 200 RetCam images.</p><p><strong>Results: </strong>The AI system exhibited favorable performance in the 3 tasks, including ROP identification [area under the receiver operating characteristic curve (AUC), 0.9531], severe ROP identification (AUC, 0.9132), and treatment modalities identification with laser photocoagulation or intravitreal injections (AUC, 0.9360). The AI system achieved an accuracy of 0.8627, a sensitivity of 0.7059, and a specificity of 0.9412 for identifying the treatment modalities of ROP. External validation results confirmed the good performance of the AI system with an accuracy of 92.0% in all 3 tasks, which was better than 4 experienced ophthalmologists who scored 56%, 65%, 71%, and 76%, respectively.</p><p><strong>Conclusions: </strong>The described AI system achieved promising outcomes in the automated identification of ROP severity and treatment modalities. Using such algorithmic approaches as accessory tools in the clinic may improve ROP screening in the future.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paracentral Acute Middle Maculopathy (PAMM) as a New Differential Diagnosis in Cherry-Red Spot Macula. 作为樱桃红斑黄斑的一种新的鉴别诊断方法的中枢旁急性中黄斑病变(PAMM)。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2022-11-04 DOI: 10.1097/APO.0000000000000542
Priyanka Singh, Hemanth Murthy
{"title":"Paracentral Acute Middle Maculopathy (PAMM) as a New Differential Diagnosis in Cherry-Red Spot Macula.","authors":"Priyanka Singh, Hemanth Murthy","doi":"10.1097/APO.0000000000000542","DOIUrl":"10.1097/APO.0000000000000542","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10632190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Unique Presentation of Bilateral Chorioretinal Atrophy. 双侧脉络膜视网膜萎缩的独特表现。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2022-10-28 DOI: 10.1097/APO.0000000000000563
Andrea Grosso, Lawrence A Yannuzzi, Stephen H Tsang, Piero Ceruti, David Sarraf, Ehud Zamir, Karolina Kaminska, Mathieu Quinodoz, Antonio Amoroso, Silvia Deaglio, Jasmine H Francis, Mauro Fioretto, Carlo Rivolta, Giacomo Calzetti
{"title":"A Unique Presentation of Bilateral Chorioretinal Atrophy.","authors":"Andrea Grosso, Lawrence A Yannuzzi, Stephen H Tsang, Piero Ceruti, David Sarraf, Ehud Zamir, Karolina Kaminska, Mathieu Quinodoz, Antonio Amoroso, Silvia Deaglio, Jasmine H Francis, Mauro Fioretto, Carlo Rivolta, Giacomo Calzetti","doi":"10.1097/APO.0000000000000563","DOIUrl":"10.1097/APO.0000000000000563","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10632195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of Goniotomy With or Without Secondary Intraocular Lens Implantation in Pediatric Glaucoma Following Cataract Surgery: A Prospective Pilot Study. 白内障手术后儿童青光眼的性腺切除术伴或不伴二次人工晶状体植入的结果:一项前瞻性的初步研究。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2023-09-22 DOI: 10.1097/APO.0000000000000637
Yu Zhang, Wan Chen, Timothy P H Lin, Xiulan Zhang, Dennis S C Lam, Weirong Chen

Purpose: To report the outcomes of a 120-degree goniotomy (GT) with or without secondary intraocular lens (IOL) implantation in glaucoma following cataract surgery (GFCS).

Design: Prospective, observational study.

Methods: Pediatric patients with GFCS who underwent standalone 120-degree GT or 120-degree GT combined with secondary IOL implantation (GT+IOL) from March 2022 to August 2022 at the Zhongshan Ophthalmic Center were recruited. Primary outcomes were intraocular pressure (IOP) and the number of ocular hypotensive medications. A secondary outcome was the surgical success rate. Success was defined as a postoperative IOP within the range of 5-21 mm Hg. Complete and qualified successes were defined, as the above, without and with ocular hypotensive medications, respectively.

Results: Thirty-two eyes of 22 patients were included. The mean age at the time of GT was 68.5 ± 29.3 months. The mean follow-up duration was 12.2 ± 2.3 months (9-15 mo). Mean IOP decreased from 30.9 ± 4.8 mm Hg on 2 (interquartile range = 1) medications at baseline to 15.8 ± 3.6 mm Hg on 0 (interquartile range = 1.5) medication at the latest visit in all eyes. The overall complete and qualified success rates were 68.8% and 90.6%, respectively. There were no significant differences in IOP, number of medications, and complete and qualified success rates between the standalone GT and GT+IOL groups at the latest follow-up at 9 months postoperatively.

Conclusions: To reduce the need for additional surgery, 120-degree GT was a safe and effective surgical treatment for GFCS in children, which could be combined with secondary IOL implantation in aphakic eyes with GFCS.

目的:报告白内障手术(GFCS)后青光眼120度角切开术(GT)伴或不伴二次人工晶状体(IOL)植入的疗效。设计:前瞻性、观察性研究。方法:招募2022年3月至2022年8月在中山眼科中心接受独立120度GT或120度GT联合二次IOL植入(GT+IOL)的儿童GFCS患者。主要结果是眼压(IOP)和眼部降压药物的数量。次要结果是手术成功率。成功定义为术后眼压在5-21范围内 毫米 汞。如上所述,完全和合格的成功分别定义为不使用和使用眼部降压药物。结果:22例患者32眼。GT时的平均年龄为68.5±29.3个月。平均随访时间为12.2±2.3个月(9-15个月)。平均眼压从30.9±4.8 mm下降 基线时2种药物(四分位间距=1)的汞柱为15.8±3.6 mm 所有眼睛在最近一次就诊时服用0(四分位数间距=1.5)药物的Hg。总体完成率和合格率分别为68.8%和90.6%。在术后9个月的最新随访中,独立的GT和GT+IOL组在IOP、药物数量以及完全和合格的成功率方面没有显著差异。结论:为了减少额外手术的需要,120度GT是一种安全有效的儿童GFCS手术治疗方法,可与GFCS无晶状体眼的二次人工晶状体植入相结合。
{"title":"Outcomes of Goniotomy With or Without Secondary Intraocular Lens Implantation in Pediatric Glaucoma Following Cataract Surgery: A Prospective Pilot Study.","authors":"Yu Zhang, Wan Chen, Timothy P H Lin, Xiulan Zhang, Dennis S C Lam, Weirong Chen","doi":"10.1097/APO.0000000000000637","DOIUrl":"10.1097/APO.0000000000000637","url":null,"abstract":"<p><strong>Purpose: </strong>To report the outcomes of a 120-degree goniotomy (GT) with or without secondary intraocular lens (IOL) implantation in glaucoma following cataract surgery (GFCS).</p><p><strong>Design: </strong>Prospective, observational study.</p><p><strong>Methods: </strong>Pediatric patients with GFCS who underwent standalone 120-degree GT or 120-degree GT combined with secondary IOL implantation (GT+IOL) from March 2022 to August 2022 at the Zhongshan Ophthalmic Center were recruited. Primary outcomes were intraocular pressure (IOP) and the number of ocular hypotensive medications. A secondary outcome was the surgical success rate. Success was defined as a postoperative IOP within the range of 5-21 mm Hg. Complete and qualified successes were defined, as the above, without and with ocular hypotensive medications, respectively.</p><p><strong>Results: </strong>Thirty-two eyes of 22 patients were included. The mean age at the time of GT was 68.5 ± 29.3 months. The mean follow-up duration was 12.2 ± 2.3 months (9-15 mo). Mean IOP decreased from 30.9 ± 4.8 mm Hg on 2 (interquartile range = 1) medications at baseline to 15.8 ± 3.6 mm Hg on 0 (interquartile range = 1.5) medication at the latest visit in all eyes. The overall complete and qualified success rates were 68.8% and 90.6%, respectively. There were no significant differences in IOP, number of medications, and complete and qualified success rates between the standalone GT and GT+IOL groups at the latest follow-up at 9 months postoperatively.</p><p><strong>Conclusions: </strong>To reduce the need for additional surgery, 120-degree GT was a safe and effective surgical treatment for GFCS in children, which could be combined with secondary IOL implantation in aphakic eyes with GFCS.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of Femtosecond Laser in Challenging Cataract Cases. 飞秒激光在白内障手术中的应用。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2023-08-14 DOI: 10.1097/APO.0000000000000627
Yong Woo Lee, Kyu Seong Cho, Joon Young Hyon, Sang Beom Han

Femtosecond laser can provide precise and customized incision of ocular tissue with excellent accuracy and predictability. Thus, femtosecond laser-assisted cataract surgery (FLACS) can theoretically enhance the safety and efficacy of cataract surgery by providing reproducible and reliable clear corneal incision, limbal relaxing incision, anterior capsulotomy, and lens fragmentation. However, thus far, the superiority of the anatomical and visual outcomes of FLACS over those of conventional cataract surgery have been unclear. Nevertheless, studies have indicated that FLACS can potentially be helpful in improving the safety of cataract surgery in challenging situations, such as zonular weakness, preexisting capsular tear, white cataract, shallow anterior chamber, and pediatric cataracts, which may contribute to enhanced visual and anatomical outcomes. In this review, we provide a summary of the application of femtosecond laser in general cataract cases. In addition, we introduce the application of FLACS in the abovementioned challenging situations and discuss the results of studies regarding the safety and outcome of FLACS in these challenging cases.

飞秒激光可以提供精确和定制的眼组织切口,具有良好的准确性和可预测性。因此,飞秒激光辅助白内障手术(FLACS)理论上可以通过提供可重复和可靠的透明角膜切口、角膜缘松弛切口、前囊切开术和晶状体碎裂术来提高白内障手术的安全性和有效性。然而,到目前为止,FLACS在解剖和视觉结果方面优于传统白内障手术的优势尚不清楚。然而,研究表明,在具有挑战性的情况下,FLACS可能有助于提高白内障手术的安全性,如小带无力、先前存在的囊膜撕裂、白色白内障、浅前房和儿童白内障,这可能有助于增强视觉和解剖结果。在这篇综述中,我们总结了飞秒激光在一般白内障病例中的应用。此外,我们介绍了FLACS在上述具有挑战性的情况下的应用,并讨论了关于FLACS在这些具有挑战性情况下的安全性和结果的研究结果。
{"title":"Application of Femtosecond Laser in Challenging Cataract Cases.","authors":"Yong Woo Lee, Kyu Seong Cho, Joon Young Hyon, Sang Beom Han","doi":"10.1097/APO.0000000000000627","DOIUrl":"10.1097/APO.0000000000000627","url":null,"abstract":"<p><p>Femtosecond laser can provide precise and customized incision of ocular tissue with excellent accuracy and predictability. Thus, femtosecond laser-assisted cataract surgery (FLACS) can theoretically enhance the safety and efficacy of cataract surgery by providing reproducible and reliable clear corneal incision, limbal relaxing incision, anterior capsulotomy, and lens fragmentation. However, thus far, the superiority of the anatomical and visual outcomes of FLACS over those of conventional cataract surgery have been unclear. Nevertheless, studies have indicated that FLACS can potentially be helpful in improving the safety of cataract surgery in challenging situations, such as zonular weakness, preexisting capsular tear, white cataract, shallow anterior chamber, and pediatric cataracts, which may contribute to enhanced visual and anatomical outcomes. In this review, we provide a summary of the application of femtosecond laser in general cataract cases. In addition, we introduce the application of FLACS in the abovementioned challenging situations and discuss the results of studies regarding the safety and outcome of FLACS in these challenging cases.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optic Nerve Head Abnormalities in Nonpathologic High Myopia and the Relationship With Visual Field. 非病理性高度近视视神经头异常及其与视野的关系。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2023-09-22 DOI: 10.1097/APO.0000000000000636
Jingwen Jiang, Yunhe Song, Kangjie Kong, Peiyuan Wang, Fengbin Lin, Xinbo Gao, Zhenyu Wang, Ling Jin, Meiling Chen, Dennis S C Lam, Robert N Weinreb, Jost B Jonas, Kyoko Ohno-Matsui, Shida Chen, Xiulan Zhang

Purpose: To describe the optic nerve head (ONH) abnormalities in nonpathologic highly myopic eyes based on swept-source optical coherence tomography (OCT) and the relationship with visual field (VF).

Design: Secondary analysis from a longitudinal cohort study.

Methods: Highly myopic patients without myopic maculopathy of category 2 or higher were enrolled. All participants underwent a swept-source OCT examination focused on ONH. We differentiated between 3 major types (optic disc morphologic abnormality, papillary/peripapillary tissue defect, and papillary/peripapillary schisis) and 12 subtypes of ONH abnormalities. The prevalence and characteristics of ONH abnormalities and the relationship with VF were analyzed.

Results: A total of 857 participants (1389 eyes) were included. Among the 1389 eyes, 91.86%, 68.61%, and 34.92% of them had at least 1, 2, or 3 ONH abnormalities, respectively, which corresponded to 29.55%, 31.79%, and 35.67% of VF defects, respectively. Among the 12 subtypes of the 3 major types, peripapillary hyperreflective ovoid mass-like structure, visible retrobulbar subarachnoid space, and prelaminar schisis were the most common, respectively. Perimetric defects corresponding to OCT abnormalities were more commonly found in eyes with peripapillary retinal detachment, peripapillary retinoschisis, and peripapillary hyperreflective ovoid mass-like structure. Glaucoma-like VF defects were more common in eyes with deep optic cups (28.17%) and with optic disc pit/pit-like change (18.92%).

Conclusions: We observed and clarified the ONH structural abnormalities in eyes with nonpathologic high myopia. These descriptions may be helpful to differentiate changes in pathologic high myopia or glaucoma.

目的:基于扫描源光学相干断层扫描(OCT)描述非病理性高度近视眼的视神经头(ONH)异常及其与视野(VF)的关系。设计:来自纵向队列研究的二次分析。方法:入选没有2类或更高级别近视黄斑病变的高度近视患者。所有参与者都接受了聚焦于ONH的扫描源OCT检查。我们区分了ONH异常的3种主要类型(视盘形态异常、乳头状/乳头状周围组织缺陷和乳头状/乳突状周围分裂)和12种亚型。分析ONH异常的发生率、特点及与VF的关系。结果:共有857名参与者(1389只眼睛)被纳入研究。在1389只眼睛中,91.86%、68.61%和34.92%的眼睛至少有1、2或3个ONH异常,分别对应于29.55%、31.79%和35.67%的VF缺陷。在3种主要类型的12种亚型中,乳头周围高反射卵球形团块状结构、可见球后蛛网膜下腔和层前分裂分别是最常见的。与OCT异常相对应的周边缺陷更常见于乳头状视网膜脱离、乳头状视网膜劈裂和乳头状高反射卵球形结构的眼睛。青光眼样VF缺陷在深视杯眼(28.17%)和视盘凹坑/凹坑样改变眼(18.92%)中更为常见。结论:我们观察并阐明了非病理性高度近视眼的ONH结构异常。这些描述可能有助于区分病理性高度近视或青光眼的变化。
{"title":"Optic Nerve Head Abnormalities in Nonpathologic High Myopia and the Relationship With Visual Field.","authors":"Jingwen Jiang, Yunhe Song, Kangjie Kong, Peiyuan Wang, Fengbin Lin, Xinbo Gao, Zhenyu Wang, Ling Jin, Meiling Chen, Dennis S C Lam, Robert N Weinreb, Jost B Jonas, Kyoko Ohno-Matsui, Shida Chen, Xiulan Zhang","doi":"10.1097/APO.0000000000000636","DOIUrl":"10.1097/APO.0000000000000636","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the optic nerve head (ONH) abnormalities in nonpathologic highly myopic eyes based on swept-source optical coherence tomography (OCT) and the relationship with visual field (VF).</p><p><strong>Design: </strong>Secondary analysis from a longitudinal cohort study.</p><p><strong>Methods: </strong>Highly myopic patients without myopic maculopathy of category 2 or higher were enrolled. All participants underwent a swept-source OCT examination focused on ONH. We differentiated between 3 major types (optic disc morphologic abnormality, papillary/peripapillary tissue defect, and papillary/peripapillary schisis) and 12 subtypes of ONH abnormalities. The prevalence and characteristics of ONH abnormalities and the relationship with VF were analyzed.</p><p><strong>Results: </strong>A total of 857 participants (1389 eyes) were included. Among the 1389 eyes, 91.86%, 68.61%, and 34.92% of them had at least 1, 2, or 3 ONH abnormalities, respectively, which corresponded to 29.55%, 31.79%, and 35.67% of VF defects, respectively. Among the 12 subtypes of the 3 major types, peripapillary hyperreflective ovoid mass-like structure, visible retrobulbar subarachnoid space, and prelaminar schisis were the most common, respectively. Perimetric defects corresponding to OCT abnormalities were more commonly found in eyes with peripapillary retinal detachment, peripapillary retinoschisis, and peripapillary hyperreflective ovoid mass-like structure. Glaucoma-like VF defects were more common in eyes with deep optic cups (28.17%) and with optic disc pit/pit-like change (18.92%).</p><p><strong>Conclusions: </strong>We observed and clarified the ONH structural abnormalities in eyes with nonpathologic high myopia. These descriptions may be helpful to differentiate changes in pathologic high myopia or glaucoma.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials. Faricimab治疗亚洲国家糖尿病黄斑水肿患者的疗效、持久性和安全性:YOSEMITE和RHINE III期试验的1年亚组分析。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2023-09-22 DOI: 10.1097/APO.0000000000000634
Susumu Ishida, Shih-Jen Chen, Toshinori Murata, Yuichiro Ogura, Paisan Ruamviboonsuk, Taiji Sakamoto, Tachie Fujita, Mika Kawano, Shino Ohsawa, Francis Abreu, Zdenka Haskova, Jane Ives, David Silverman, Young Hee Yoon

Purpose: To assess the 1-year efficacy, durability, and safety of faricimab in patients with diabetic macular edema from Asian and non-Asian countries.

Design: Global, multicenter, randomized, double-masked, active comparator-controlled, phase III trials.

Methods: Subgroup analysis of patients from Asian (N=144) and non-Asian (N=1747) countries randomized to faricimab 6.0 mg every 8 weeks (Q8W), faricimab per personalized treatment interval (PTI), or aflibercept 2.0 mg Q8W in the YOSEMITE/RHINE (NCT03622580/NCT03622593) trials. Primary endpoint: best-corrected visual acuity (BCVA) changes from baseline at 1 year, averaged over weeks 48, 52, and 56.

Results: Mean BCVA change from baseline at 1 year in the Asian country subgroup was similar between arms: faricimab Q8W (n=50), +10.9 (95% CI: 8.6-13.2); faricimab PTI (n=48) +10.0 (7.7-12.4) letters; aflibercept Q8W (n=46) +9.0 (6.6-11.4) letters. BCVA gains in the non-Asian country subgroup (n=582, 584, 581) were +11.3 (10.5-12.1), +11.2 (10.5-12.0), and +10.7 (9.9-11.5) letters, respectively. At 1 year, 49% of Asian country patients in the faricimab PTI arm achieved Q16W dosing (vs. 52% non-Asian) and 78% achieved ≥Q12W dosing (vs. 72% non-Asian). Anatomic improvementswere generally greater with faricimab versus aflibercept and similar between the Asian and non-Asian country subgroups. Faricimab was well tolerated, with no new safety signals.

Conclusions: Vision, durability, anatomic, and safety outcomes were generally similar between the Asian and non-Asian country subgroups, suggesting that global YOSEMITE/RHINE results may be generalized to the Asian population. These data support the benefit-risk profile of faricimab for treating Asian patients with diabetic macular edema.

目的:评估法利昔单抗治疗亚洲和非亚洲国家糖尿病黄斑水肿患者的1年疗效、耐用性和安全性。设计:全球、多中心、随机、双盲、活性对照、III期试验。方法:对来自亚洲(N=144)和非亚洲(N=1747)国家的患者进行亚组分析,这些患者在YOSEMITE/RHINE(NCT03622580/NCT03622593)试验中随机接受法利昔单抗6.0 mg每8周一次(Q8W)、法利昔mab每个性化治疗间隔(PTI)或阿法西普2.0 mg Q8W。主要终点:1年时最佳矫正视力(BCVA)与基线的变化,平均在第48、52和56周。结果:亚洲国家亚组1年时的平均BCVA变化在两组之间相似:法利昔单抗Q8W(n=50),+10.9(95%CI:8.6-13.2);faricimab PTI(n=48)+10.0(7.7-12.4)个字母;aflibercept Q8W(n=46)+9.0(6.6-11.4)个字母。非亚洲国家亚组(n=582584581)的BCVA增益分别为+11.3(10.5-12.1)、+11.2(10.5-12.0)和+10.7(9.9-11.5)个字母。在1年时,法利昔单抗PTI组中49%的亚洲国家患者达到Q16W给药(非亚裔患者占52%),78%的患者达到≥Q12W给药(亚裔患者占72%)。faricimab与aflibercept相比,解剖改善通常更大,亚洲和非亚洲国家亚组之间的改善相似。Faricimab耐受性良好,没有新的安全信号。结论:亚洲和非亚洲国家亚组的视力、耐用性、解剖学和安全性结果总体相似,这表明全球YOSEMITE/RHINE结果可能适用于亚洲人群。这些数据支持法利昔单抗治疗亚洲糖尿病黄斑水肿患者的获益风险概况。
{"title":"Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.","authors":"Susumu Ishida, Shih-Jen Chen, Toshinori Murata, Yuichiro Ogura, Paisan Ruamviboonsuk, Taiji Sakamoto, Tachie Fujita, Mika Kawano, Shino Ohsawa, Francis Abreu, Zdenka Haskova, Jane Ives, David Silverman, Young Hee Yoon","doi":"10.1097/APO.0000000000000634","DOIUrl":"10.1097/APO.0000000000000634","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the 1-year efficacy, durability, and safety of faricimab in patients with diabetic macular edema from Asian and non-Asian countries.</p><p><strong>Design: </strong>Global, multicenter, randomized, double-masked, active comparator-controlled, phase III trials.</p><p><strong>Methods: </strong>Subgroup analysis of patients from Asian (N=144) and non-Asian (N=1747) countries randomized to faricimab 6.0 mg every 8 weeks (Q8W), faricimab per personalized treatment interval (PTI), or aflibercept 2.0 mg Q8W in the YOSEMITE/RHINE (NCT03622580/NCT03622593) trials. Primary endpoint: best-corrected visual acuity (BCVA) changes from baseline at 1 year, averaged over weeks 48, 52, and 56.</p><p><strong>Results: </strong>Mean BCVA change from baseline at 1 year in the Asian country subgroup was similar between arms: faricimab Q8W (n=50), +10.9 (95% CI: 8.6-13.2); faricimab PTI (n=48) +10.0 (7.7-12.4) letters; aflibercept Q8W (n=46) +9.0 (6.6-11.4) letters. BCVA gains in the non-Asian country subgroup (n=582, 584, 581) were +11.3 (10.5-12.1), +11.2 (10.5-12.0), and +10.7 (9.9-11.5) letters, respectively. At 1 year, 49% of Asian country patients in the faricimab PTI arm achieved Q16W dosing (vs. 52% non-Asian) and 78% achieved ≥Q12W dosing (vs. 72% non-Asian). Anatomic improvementswere generally greater with faricimab versus aflibercept and similar between the Asian and non-Asian country subgroups. Faricimab was well tolerated, with no new safety signals.</p><p><strong>Conclusions: </strong>Vision, durability, anatomic, and safety outcomes were generally similar between the Asian and non-Asian country subgroups, suggesting that global YOSEMITE/RHINE results may be generalized to the Asian population. These data support the benefit-risk profile of faricimab for treating Asian patients with diabetic macular edema.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Corneal Nerve Regeneration After Minimally Invasive Corneal Neurotization. 微创角膜神经化术后角膜神经再生的评价。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2023-09-01 Epub Date: 2023-07-25 DOI: 10.1097/APO.0000000000000626
Dai Su, Jiaying Zhang, Yue Wu, Wenjin Wang, Wei Wang, Chunyi Shao, Jin Li

Purpose: To evaluate the corneal nerve regeneration after minimally invasive corneal neurotization (MICN) and to further clarify the recovery patterns of sensory and trophic functions of the corneal nerves.

Design: A retrospective cohort study based in the Shanghai Ninth People's Hospital.

Methods: Eighteen patients (18 eyes) who underwent MICN for neurotrophic keratopathy due to intracranial surgery was conducted to analyze their follow-up data at 6, 12, 18, and 24 months after surgery.

Results: At 12 months postoperatively, the growth of the central and peripheral corneal nerve fiber density (CNFD) was 11.47±8.56 and 14.73±8.08 n/mm 2 with subsequent improvement slowing down, and the patient's corneal epithelium defect was healed ahead of the accomplishment of corneal nerve regeneration. The number of dendritic cells also reached its peak. At 18 months postoperatively, the recovery of central and peripheral corneal sensation was 37.22±23.06 mm and 39.38±18.08 mm with no subsequent improvement, and the growth of the central and peripheral corneal nerve branch density (CNBD) was 29.69±11.05 and 43.75±1.41 n/mm 2 , with a positive and significant correlation between corneal sensation and CNBD (at central r =0.632, P <0.005; at peripheral r =0.645, P <0.005). At 24 months postoperatively, mean CNFD, CNBD, and corneal sensation recovered significantly compared with preoperative, but a few patients' corneal sensation recovered insignificantly with good CNFD recovery and poor CNBD recovery.

Conclusions: After MICN, the trophic function of the corneal nerve recovers before the sensory function, and in particular, the recovery of sensation is based on the coexistence of the corneal nerve trunk and branches.

目的:评价微创角膜神经化术(MICN)后角膜神经再生情况,进一步阐明角膜神经感觉和营养功能的恢复模式。设计:基于上海市第九人民医院的回顾性队列研究。方法:对18例(18眼)因颅内手术而接受神经营养性角膜病变MICN的患者在术后6、12、18和24个月的随访数据进行分析。结果:术后12个月,角膜中央和外周神经纤维密度(CNFD)的增长分别为11.47±8.56和14.73±8.08n/mm2,随后的改善速度减慢,患者角膜上皮缺损在完成角膜神经再生之前愈合。树突细胞的数量也达到了峰值。术后18个月,角膜中央和外周感觉的恢复分别为37.22±23.06mm和39.38±18.08mm,但无明显改善;角膜中央和周围神经分支密度(CNBD)的生长分别为29.69±11.05和43.75±1.41n/mm2,角膜感觉与CNBD呈正相关(中心r=0.632,P结论:MICN后,角膜神经的营养功能先于感觉功能恢复,尤其是感觉的恢复是基于角膜神经干和分支的共存。
{"title":"Evaluation of Corneal Nerve Regeneration After Minimally Invasive Corneal Neurotization.","authors":"Dai Su, Jiaying Zhang, Yue Wu, Wenjin Wang, Wei Wang, Chunyi Shao, Jin Li","doi":"10.1097/APO.0000000000000626","DOIUrl":"10.1097/APO.0000000000000626","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the corneal nerve regeneration after minimally invasive corneal neurotization (MICN) and to further clarify the recovery patterns of sensory and trophic functions of the corneal nerves.</p><p><strong>Design: </strong>A retrospective cohort study based in the Shanghai Ninth People's Hospital.</p><p><strong>Methods: </strong>Eighteen patients (18 eyes) who underwent MICN for neurotrophic keratopathy due to intracranial surgery was conducted to analyze their follow-up data at 6, 12, 18, and 24 months after surgery.</p><p><strong>Results: </strong>At 12 months postoperatively, the growth of the central and peripheral corneal nerve fiber density (CNFD) was 11.47±8.56 and 14.73±8.08 n/mm 2 with subsequent improvement slowing down, and the patient's corneal epithelium defect was healed ahead of the accomplishment of corneal nerve regeneration. The number of dendritic cells also reached its peak. At 18 months postoperatively, the recovery of central and peripheral corneal sensation was 37.22±23.06 mm and 39.38±18.08 mm with no subsequent improvement, and the growth of the central and peripheral corneal nerve branch density (CNBD) was 29.69±11.05 and 43.75±1.41 n/mm 2 , with a positive and significant correlation between corneal sensation and CNBD (at central r =0.632, P <0.005; at peripheral r =0.645, P <0.005). At 24 months postoperatively, mean CNFD, CNBD, and corneal sensation recovered significantly compared with preoperative, but a few patients' corneal sensation recovered insignificantly with good CNFD recovery and poor CNBD recovery.</p><p><strong>Conclusions: </strong>After MICN, the trophic function of the corneal nerve recovers before the sensory function, and in particular, the recovery of sensation is based on the coexistence of the corneal nerve trunk and branches.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9920518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asia-Pacific Journal of Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1